- Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
-
Kadaru T, Shibli-Rahhal A
- KMID: 2513878
- J Bone Metab.
- 2021 Feb;28(1):51-58.
- doi: 10.11005/jbm.2021.28.1.51
Background: Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are... -
- CITED
-
- Close
- SHARE
-
- Close
